TCX-201 / Tacalyx - LARVOL DELTA

Two novel antibodies targeting different tumor-associated carbohydrate (TACA) antigens for the treatment of solid tumors show promising preclinical activity using different modes of action (AACR 2025) - "We focus on the generation of antibodies against these specific and difficult antigens and were able to obtain two high-affinity monoclonal antibodies (mAbs), TCX-101 and TCX-201, against two distinct TACA structures that are highly expressed across a broad range of cancer indications. In vitro studies show effective killing of various pancreatic (e.g. high expressing HuP-T4 cells with an IC50 for MMAE payload of 0.3 nM) and colon cancer cell lines expressing different levels of the target (e.g. Colo-205 (high expressing) with an IC50 of 0.013 nM or LS180 (medium expressing) with an IC50 of 4.7 nM), and high efficacy for both payloads in a xenograft mouse model using HuP-T4 pancreatic cancer cells. In conclusion, our antibodies against TACAs represent new promising treatment options for different cancer indications and can be effectively employed with different modes of action, depending on the target characteristics."

Preclinical • Colon Cancer • Colorectal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor